Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling.
Postmenopausal osteoporosis (PMOP) is a metabolic bone disorder driven by excessive osteoclast (OC) activity, but current therapies are limited by adverse effects. Trans-zeatin (TZ), a naturally occurring plant cytokinin with antioxidant properties, has not been investigated in bone metabolism. Here, we show that TZ su...